-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, Bristol-Myers Squibb (BMS) announced that its blockbuster PD-1 inhibitor Odivo (Navulimab) is combined with chemotherapy to treat patients with early-stage non-small cell lung cancer Positive results at the time.
As a neoadjuvant therapy before surgery, Odivo's combination therapy increased the patient's complete pathological response rate (pCR) to 24%, compared with 2.
2% in the chemotherapy group.
Complete tumor pathological remission means that no cancer cells are found in the surgically removed specimens.
The press release pointed out that this is the first phase 3 clinical trial in patients with resectable non-small cell lung cancer to show that neoadjuvant immune combination therapy can significantly improve the pathological response.
Lung cancer is one of the leading causes of cancer deaths worldwide.
Non-small cell lung cancer (NSCLC) is the most common in lung cancer, accounting for 84% of all confirmed cases.
Most NSCLC patients (about 60%) have not yet metastasized at the time of diagnosis.
Although many NSCLC patients have undergone surgery, there are still 30% to 55% of patients who will relapse after surgery and die as a result.
Therefore, a variety of treatment options are needed, including neoadjuvant treatment before surgery and adjuvant treatment after surgery, to prolong the life of the patient.
Odivo is a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb.
It helps T lymphocytes to restore anti-tumor immune response by blocking the immunosuppressive signal mediated by PD-1.
In a randomized, open-label, phase 3 clinical trial called CheckMate-816, patients with resectable NSCLC from stages Ib to IIIa received 3 cycles of Odivo and chemotherapy before surgery, or chemotherapy.
The test results showed that in addition to significantly improving the tumor pathological complete remission rate, the Odivo combination therapy also significantly improved the patient’s primary pathological remission (MPR), which is defined as a reduction in the proportion of tumor cells in surgically removed samples to 10% or less.
The main pathological remission rate of patients in the Odivo combination therapy group was 36.
9%, which was 4 times that of the chemotherapy alone group (8.
9%).
At the same time, more patients who received Odivo's combination neoadjuvant therapy received surgery, and the proportion of patients in the Odivo combination group who achieved complete tumor resection was higher.
"The ultimate goal of early-stage cancer treatment is to prevent the recurrence of cancer, and at the same time strive to find a cure for the patient.
Unfortunately, even in patients undergoing surgery, more than half of the patients' cancer will come back.
" France Curie Institute Dr.
Nicolas Girard, Director of the Medical Oncology Department, said: "The complete pathological remission data of CheckMate-816 provides us with early evidence that Odivo combined with chemotherapy as a neoadjuvant treatment for NSCLC is expected to bring potential benefits to patients.
We hope this Encouraging results can ultimately extend the patient’s event-free survival and ultimately the overall survival.
"Reference: [1] Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial.
Retrieved April 11, 2021, from https://investors.
bms.
com/iframes/press-releases/press-release-details/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Pathologic-Complete-Response-in-Patients-with-Resectable-Non-Small- Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.
aspx Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital .
As a neoadjuvant therapy before surgery, Odivo's combination therapy increased the patient's complete pathological response rate (pCR) to 24%, compared with 2.
2% in the chemotherapy group.
Complete tumor pathological remission means that no cancer cells are found in the surgically removed specimens.
The press release pointed out that this is the first phase 3 clinical trial in patients with resectable non-small cell lung cancer to show that neoadjuvant immune combination therapy can significantly improve the pathological response.
Lung cancer is one of the leading causes of cancer deaths worldwide.
Non-small cell lung cancer (NSCLC) is the most common in lung cancer, accounting for 84% of all confirmed cases.
Most NSCLC patients (about 60%) have not yet metastasized at the time of diagnosis.
Although many NSCLC patients have undergone surgery, there are still 30% to 55% of patients who will relapse after surgery and die as a result.
Therefore, a variety of treatment options are needed, including neoadjuvant treatment before surgery and adjuvant treatment after surgery, to prolong the life of the patient.
Odivo is a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb.
It helps T lymphocytes to restore anti-tumor immune response by blocking the immunosuppressive signal mediated by PD-1.
In a randomized, open-label, phase 3 clinical trial called CheckMate-816, patients with resectable NSCLC from stages Ib to IIIa received 3 cycles of Odivo and chemotherapy before surgery, or chemotherapy.
The test results showed that in addition to significantly improving the tumor pathological complete remission rate, the Odivo combination therapy also significantly improved the patient’s primary pathological remission (MPR), which is defined as a reduction in the proportion of tumor cells in surgically removed samples to 10% or less.
The main pathological remission rate of patients in the Odivo combination therapy group was 36.
9%, which was 4 times that of the chemotherapy alone group (8.
9%).
At the same time, more patients who received Odivo's combination neoadjuvant therapy received surgery, and the proportion of patients in the Odivo combination group who achieved complete tumor resection was higher.
"The ultimate goal of early-stage cancer treatment is to prevent the recurrence of cancer, and at the same time strive to find a cure for the patient.
Unfortunately, even in patients undergoing surgery, more than half of the patients' cancer will come back.
" France Curie Institute Dr.
Nicolas Girard, Director of the Medical Oncology Department, said: "The complete pathological remission data of CheckMate-816 provides us with early evidence that Odivo combined with chemotherapy as a neoadjuvant treatment for NSCLC is expected to bring potential benefits to patients.
We hope this Encouraging results can ultimately extend the patient’s event-free survival and ultimately the overall survival.
"Reference: [1] Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial.
Retrieved April 11, 2021, from https://investors.
bms.
com/iframes/press-releases/press-release-details/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Pathologic-Complete-Response-in-Patients-with-Resectable-Non-Small- Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.
aspx Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital .
